Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine feasibility study for major depressive disorder in palliative care
ACTRN12618001586202Phase 2Terminated
- Sponsor
- University of Technology Sydney
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of Technology Sydney. Primary endpoint: Study feasibility. Started Sep 2019; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12618001586202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001586202.